What if you'd held SYRE?
A $1,000 investment in Spyre Therapeutics, Inc. (SYRE) at the month-end close of 2016-04 would be worth $497 at the close of 2026-08 — -50.3% total return, dividends reinvested. The same $1,000 in the S&P 500 would be worth $3,732.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-08, dividends included.
Every year, $1,000 from 2016
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2016 | $1,000 | — |
| 2017 | $1,244 | +24.4% |
| 2018 | $1,722 | +38.4% |
| 2019 | $1,756 | +2.0% |
| 2020 | $1,809 | +3.0% |
| 2021 | $1,092 | -39.6% |
| 2022 | $103 | -90.5% |
| 2023 | $198 | +91.3% |
| 2024 | $214 | +8.2% |
| 2025 | $301 | +40.7% |
| 2026 | $1,002 | +232.5% |
Best and worst month-end to buy
The best single month-end close to have bought SYRE was 2023-05 ($3.25): $1,000 then is $33,514 today. The worst was 2018-08 ($273): $1,000 then is $399.
FAQ
What would $1,000 in SYRE be worth today?
A $1,000 investment in Spyre Therapeutics, Inc. (SYRE) at the start of 2016 would be worth about $497 today, a total return of -50.3%. Dividends are reinvested in these figures.
What were the best and worst years for SYRE?
Spyre Therapeutics, Inc. (SYRE)'s strongest calendar year since 2016 was 2026, a +232.5% return — $1,000 held through that year became about $3,325 by year-end. Its weakest year was 2022, at -90.5%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in SYRE have grown?
Investing $100 at the end of every month since 2016-04 would have grown to about $39,378 on $12,500 invested.
Did SYRE beat the S&P 500?
Over the same period, $1,000 in the S&P 500 index would be worth $3,732. SYRE trailed the S&P 500 by +86.7% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Spyre Therapeutics, Inc. (SYRE) historical total-return data from 2016-04 to 2026-08, reduced to month-end closes for the tables above.
Returns use adjusted close prices from Yahoo Finance historical data — adjusted for stock splits and reinvested dividends — the same convention used by major brokerages. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (Yahoo Finance): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via Yahoo Finance. As of 2026-08. Not financial advice.